[Short-term effect of paclitaxel-eluting stent in the treatment of coronary heart disease due to coronary arteriosclerosis].
OBJECTIVE
To evaluate the short-term safety and efficacy of paclitaxel-eluting stent (TAXUS stent, Boston Scientific) in the treatment of coronary heart disease (CHD) due to coronary arteriosclerosis.


METHODS
From July 2003 to November 2004, 300 consecutive patients with CHD due to coronary arteriosclerosis were admitted for selective percutaneous coronary intervention (PCI) and paclitaxel-eluting stent implantation in the coronary arteries. The immediate effects after PCI and follow-up results were investigated.


RESULTS
Altogether 350 lesions were treated and 355 paclitaxel-eluting stents implanted in the 300 cases. Of these lesions, 248 (70.9%) was complicated lesions of B2 type or worse, 94 (26.5%) small-caliber stents (2.50-2.75 mm) and 130 (36.6%) long stents (>20 mm) were implanted, without occurrence of severe intra-operative complications. Follow-up study of 250 cases (83.3%) lasting for 1 to 15 months was conducted, and chest pain was reported in 8 cases, 2 of which underwent coronary artery angiography and no in-stent restenosis was found. One patient developed myocardial infarction 5 months after PCI, and 2 died for non-cardiogenic factors.


CONCLUSIONS
Paclitaxel-eluting stent implantation in patients undergoing PCI is safe approach with good short-term efficacy.
Wan
Hai-yan
HY
Department of Cardiology, Wuhan Asia Heart Disease Hospital, Wuhan 430022, China.
Zhu
Guo-ying
GY
Wang
Ren-peng
RP
Su
Xi
X
Peng
Jian
J
Song
Dan
D
Chen
Guo-hong
GH
D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000379:methods; D003324:Coronary Artery Disease / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000627:therapeutic use*; D015607:Stents
D017239:Paclitaxel